3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
93
Stomach Neoplasms
56
Rectal Neoplasms
51
Colonic Neoplasms
47
Pancreatic Neoplasms
21
Neoplasms
14
Carcinoma, Hepatocellular
14
Neoplasm Metastasis
13
Adenocarcinoma
10
Parkinson Disease 4, Autosomal Dominant Lewy Body
9
Lymphoma, Large B-Cell, Diffuse
9
Cholangiocarcinoma
8
Adenocarcinoma Of Esophagus
8
Esophageal Neoplasms
5
Biliary Tract Neoplasms
5
Neurotoxicity Syndromes
4
Esophageal Squamous Cell Carcinoma
4
Lymphoma, Extranodal NK-T-Cell
3
Gastrointestinal Neoplasms
3
Gallbladder Neoplasms
3
Peritoneal Neoplasms
2
Lymphoma
2
Liver Neoplasms
2
Hepatoblastoma
2
Gastrointestinal Diseases
2
Colorectal Adenocarcinoma
2
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Teratoma
1
Spinocerebellar Degenerations
1
Interventions
Carboplatin
17
Cisplatin
14
Paclitaxel
12
Pemetrexed
11
pembrolizumab
9
Gemcitabine
7
Docetaxel
6
Sorafenib
5
osimertinib
4
durvalumab
4
130-nm albumin-bound paclitaxel
4
padeliporfin
3
cabozantinib
3
atezolizumab
3
Taxes
3
Radiotherapy
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Cetuximab
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
trifluridine tipiracil drug combination
2
regorafenib
2
olaparib
2
Sunitinib
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Nivolumab
2
Irinotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma
×
Oxaliplatin
×
Clear all
NCT02539537
2024-01-09
NEOPAN
UNICANCER
Phase 3
Completed
171 enrolled